Catalog No.: PC-61474Not For Human Use, Lab Use Only.
Ladarixin (DF 2156) is an allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM.
Ladarixin (DF 2156) is an allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM.
Ladarixin (DF 2156) prevents PMN infiltration and tissue damage in several models of IR injury in vivo.
Ladarixin (DF 2156) abrogates motility and induces apoptosis in cultured cutaneous and uveal melanoma cells and xenografts.
Ladarixin (DF 2156) also prevents inflammation-mediated damage in MLD-STZ, prevents and reverses diabetes in NOD mice.
